Exhibit 99.1
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
3Q 2023 Total Revenue of $103.5M, a 27% Increase Year-Over-Year and 22% at CER
Galafold® Quarterly Revenue Surpasses $100M for the First Time
Increasing FY 2023 Galafold® Revenue Growth Guidance to 16%-18% at CER
Pombiliti™ + Opfolda™ Approved and Launched in the U.S., EU and U.K.
Non-GAAP Profitability Projected in Q4 2023
Conference Call and Webcast Today at 8:30 a.m. ET
PRINCETON, NJ, Nov. 8, 2023 – Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the third quarter ended September 30, 2023.
Bradley Campbell, President and Chief Executive Officer of Amicus Therapeutics, Inc., stated, “This has been a monumental quarter for Amicus highlighted by the U.S. and U.K. approvals of Pombiliti and Opfolda, the global launches of Pombiliti and Opfolda, as well as the continued strong growth of Galafold worldwide. We are now approved in the three largest Pompe markets and are making tremendous progress on our second commercial launch. In addition to the commercial successes, we are well on track to achieve all of our annual strategic priorities, including non-GAAP profitability in the fourth quarter. I am proud of everyone at Amicus who has worked so hard to make a difference in the lives of people living with rare diseases.”
Recent Corporate Highlights:
| · | Total revenues were $103.5 million in the third quarter 2023, a year-over-year increase of 27%, or 22% at constant exchange rates (CER)1. |
| Three Months Ended September 30, | Year over Year % Growth | Nine Months Ended September 30, | Year over Year % Growth | |||||||||||||||||||||||||||||
| (in thousands) | 2023 | 2022 | Reported | at CER1 | 2023 | 2022 | Reported | at CER1 | ||||||||||||||||||||||||
| Galafold® | 100,733 | 81,631 | 23 | % | 19 | % | 281,177 | 241,056 | 17 | % | 17 | % | ||||||||||||||||||||
| Pombiliti™ + Opfolda™ | 2,768 | 60 | n/a | n/a | 3,097 | 81 | n/a | n/a | ||||||||||||||||||||||||
| Net Product Revenues | $ | 103,501 | $ | 81,691 | 27 | % | 22 | % | $ | 284,274 | $ | 241,137 | 18 | % | 18 | % | ||||||||||||||||
| · | Galafold (migalastat) net product sales were $100.7 million in the third quarter 2023, a year-over-year increase of 23%, or 19% at CER1. |
| · | Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) approved in the U.S., EU, and U.K. The commercial launch of Pombiliti + Opfolda is successfully underway in the three largest markets. Net product sales in the third quarter were $2.8 million. Third quarter revenue represents commercial sales in Germany and the U.K. |
| · | Amicus entered into a definitive agreement for a $430 million refinancing collaboration with Blackstone. Blackstone Life Sciences and Blackstone Credit have agreed to provide Amicus with a $400 million senior secured term loan facilitating a refinancing of existing debt under more favorable terms and a $30 million strategic investment in Amicus common stock. |
| · | Full-year 2023 non-GAAP operating expense guidance of $330 million to $350 million, driven by prudent expense management while investing in Pombiliti + Opfolda manufacturing and launch activities. |
| · | Based on the current operating plan, the Company is on-track to achieve non-GAAP profitability2 in the fourth quarter of 2023, a major milestone for Amicus. |
1
Third Quarter 2023 Financial Results
| · | Total revenue in the third quarter 2023 was $103.5 million, a year-over-year increase of 27% from total revenue of $81.7 million in the third quarter 2022. On a constant currency basis, third quarter 2023 total revenue growth was 22%. Currency impact on reported revenue in the third quarter of 2023 represented a benefit of $3.8 million, or 5%. |
| · | Total GAAP operating expenses of $110.6 million for the third quarter 2023 increased by 8% as compared to $102.1 million for the third quarter 2022. |
| · | Total non-GAAP operating expenses of $89.8 million for the third quarter 2023 increased by 5% as compared to $85.5 million for the third quarter 2022.3 |
| · | Net loss was reduced to $21.6 million, or $0.07 per share for the third quarter 2023, compared to a net loss of $33.3 million, or $0.12 per share, for the third quarter 2022. |
| · | Cash, cash equivalents, and marketable securities totaled $280.3 million at September 30, 2023, compared to $293.6 million at December 31, 2022. |
2023 Financial Guidance
| · | For the full-year 2023, the Company is increasing the Galafold revenue growth guidance to between 16 and 18% at CER1 driven by several factors including continued strong underlying demand from both switch and treatment-naïve patients, further geographic expansion and label extensions, the continued diagnosis of new Fabry patients, and commercial execution across all major markets, including the U.S., EU, U.K., and Japan. |
| · | Non-GAAP operating expense guidance for the full-year 2023 is $330 million to $350 million, driven by prudent expense management offset by continued investment in Galafold, AT-GAA clinical studies, non-recurring costs for manufacturing as well as global launch activities4. |
| · | The Company is on-track to achieve non-GAAP profitability2 in the fourth quarter of 2023. |
Amicus is focused on the following five key strategic priorities in 2023:
| · | Sustain double-digit Galafold revenue growth (16-18% at CER1) |
| · | Secure EMA, MHRA and FDA approvals for Pombiliti + Opfolda |
| · | Initiate successful global launches of Pombiliti + Opfolda |
| · | Advance next-generation pipeline programs (Fabry GTx, Fabry Next-Generation Chaperone, Pompe GTx) |
| · | Maintain strong financial position on path to profitability |
1 In order to illustrate underlying performance, Amicus discusses its results in terms of constant exchange rate (CER) growth. This represents growth calculated as if the exchange rates had remained unchanged from those used in the comparative period. Full-year 2023 Galafold revenue guidance utilizes the actual exchange rates at December 31, 2022.
2 Based on projections of Amicus’ non-GAAP Net Income under current operating plans. Amicus defines non-GAAP Net Income as GAAP Net Income excluding the impact of stock-based compensation expense, changes in fair value of contingent consideration, loss on impairment of assets, depreciation and amortization, acquisition-related income (expense), loss on extinguishment of debt, restructuring charges and income taxes.
3 Full reconciliation of GAAP results to the Company’s non-GAAP adjusted measures for all reporting periods appears in the tables to this press release.
4 A reconciliation of the differences between the non-GAAP expectation and the corresponding GAAP measure is not available without unreasonable effort due to high variability, complexity, and low visibility as to the items that would be excluded from the GAAP measure.
Conference Call and Webcast
Amicus Therapeutics will host a conference call and audio webcast today, November 8, 2023, at 8:30 a.m. ET to discuss the third quarter 2023 financial results and corporate updates. Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event.
A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com. Web participants are encouraged to register on the website 15 minutes prior to the start of the call. An archived webcast and accompanying slides will be available on the Company's website shortly after the conclusion of the live event.
About Galafold
Galafold® (migalastat) 123 mg capsules is an oral pharmacological chaperone of alpha-Galactosidase A (alpha-Gal A) for the treatment of Fabry disease in adults who have amenable galactosidase alpha gene (GLA) variants. In these patients, Galafold works by stabilizing the body’s own dysfunctional enzyme so that it can clear the accumulation of disease substrate. Globally, Amicus Therapeutics estimates that approximately 35 to 50 percent of Fabry patients may have amenable GLA variants, though amenability rates within this range vary by geography. Galafold is approved in more than 40 countries around the world, including the U.S., EU, U.K., and Japan.
2
U.S. INDICATIONS AND USAGE
Galafold is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.
This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
U.S. IMPORTANT SAFETY INFORMATION
ADVERSE REACTIONS
The most common adverse drug reactions reported with Galafold (≥10 %) are headache, nasopharyngitis, urinary tract infection, nausea, and pyrexia.
DRUG INTERACTIONS
Avoid co-administration of Galafold with caffeine at least 2 hours before and 2 hours after taking Galafold.
USE IN SPECIFIC POPULATIONS
There is insufficient clinical data on Galafold use in pregnant women to inform a drug-associated risk for major birth defects and miscarriage. Advise women of the potential risk to a fetus.
It is not known if Galafold is present in human milk. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Galafold and any potential adverse effects on the breastfed child from Galafold or from the underlying maternal condition.
Galafold is not recommended for use in patients with severe renal impairment or end-stage renal disease requiring dialysis.
The safety and effectiveness of Galafold have not been established in pediatric patients.
To report Suspected Adverse Reactions, contact Amicus Therapeutics at 1-877-4AMICUS or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
For additional information about Galafold, including the full U.S. Prescribing Information, please visit https://www.amicusrx.com/pi/Galafold.pdf.
EU Therapeutic Indication
Galafold® (migalastat) is indicated for long-term treatment of adults and adolescents aged 12 years and older with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency) and who have an amenable mutation.
EU Important Safety Information
Treatment with Galafold should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of Fabry disease. Galafold is not intended for concomitant use with enzyme replacement therapy.
The safety and efficacy of Galafold in children aged less than 12 years have not been established. No data are available.
Galafold is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients listed in the Summary of Product Characteristics (SmPC).
Galafold 123 mg capsules are not for children (≥12 years) weighing less than 45 kg.
It is advised to periodically monitor renal function, echocardiographic parameters and biochemical markers (every 6 months) in patients initiated on or switched to Galafold. In case of meaningful clinical deterioration, further clinical evaluation or discontinuation of treatment with Galafold should be considered.
Galafold is not indicated for use in patients with non-amenable mutations.
Galafold is not recommended for use in patients with severe renal insufficiency, defined as estimated GRF less than 30 mL/min/1.73m2.
Food and caffeine should not be consumed at least 2 hours before and 2 hours after taking Galafold to give a minimum 4 hours fast.
Galafold is not recommended in women of childbearing potential not using contraception. Galafold is not recommended during pregnancy. It is not known whether Galafold is secreted in human milk.
3
The most common adverse reaction reported was headache, which was experienced by approximately 10% of patients who received Galafold. For a complete list of adverse reactions, please review the SmPC.
OVERDOSE: General medical care is recommended in the case of Galafold overdose.
For complete information please see the EU SmPC available at https://www.ema.europa.eu/en/medicines/human/EPAR/galafold
About Pombiliti + Opfolda
Pombiliti + Opfolda, is a two-component therapy that consists of cipaglucosidase alfa-atga, a bis-M6P-enriched rhGAA that facilitates high-affinity uptake through the M6P receptor while retaining its capacity for processing into the most active form of the enzyme, and the oral enzyme stabilizer, miglustat, that’s designed to reduce loss of enzyme activity in the blood.
U.S. INDICATIONS AND USAGE
POMBILITI in combination with OPFOLDA is indicated for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT).
SAFETY INFORMATION
HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS: Appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily available. If a severe hypersensitivity reaction occurs, POMBILITI should be discontinued immediately and appropriate medical treatment should be initiated. INFUSION-ASSOCIATED REACTIONS (IARs): If severe IARs occur, immediately discontinue POMBILITI and initiate appropriate medical treatment. RISK OF ACUTE CARDIORESPIRATORY FAILURE IN SUSCEPTIBLE PATIENTS: Patients susceptible to fluid volume overload, or those with acute underlying respiratory illness or compromised cardiac or respiratory function, may be at risk of serious exacerbation of their cardiac or respiratory status during POMBILITI infusion. See PI for complete Boxed Warning. CONTRAINDICATION: POMBILITI in combination with Opfolda is contraindicated in pregnancy. EMBRYO-FETAL TOXICITY: May cause embryo-fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception during treatment and for at least 60 days after the last dose. Adverse Reactions: Most common adverse reactions ≥ 5% are headache, diarrhea, fatigue, nausea, abdominal pain, and pyrexia. Please see full PRESCRIBING INFORMATION, including BOXED WARNING, for POMBILITI (cipaglucosidase alfa-atga) LINK and full PRESCRIBING INFORMATION for OPFOLDA (miglustat) LINK.
EU Important Safety Information
Pombiliti (cipaglucosidase alfa) Important Safety Information
Posology and Method of Administration: Pombiliti must be used in combination with miglustat 65 mg hard capsules. The recommended dose of Pombiliti is 20 mg/kg of body weight every other week. The Pombiliti infusion should start 1 hour after taking miglustat capsules. Paediatric population: The safety and efficacy of Pombiliti in combination with miglustat therapy in paediatric patients less than 18 years old have not yet been established. No data are available. Contraindications: Life-threatening hypersensitivity to the active substance, or to any of the excipients. Contraindication to miglustat. Anaphylaxis and infusion-associated reactions (IARs): Serious anaphylaxis and IARs have occurred in some patients during infusion and following infusion with Pombiliti. Premedication with oral antihistamine, antipyretics, and/or corticosteroids may be administered to assist with signs and symptoms related to IARs experienced with prior enzyme replacement therapy (ERT) treatment. Reduction of the infusion rate, temporary interruption of the infusion, symptomatic treatment with oral antihistamine, or antipyretics, and appropriate resuscitation measures should be considered to manage serious IARs. If anaphylaxis or severe allergic reactions occur, infusion should be immediately paused, and appropriate medical treatment should be initiated. The current medical standards for emergency treatment of anaphylactic reactions are to be observed and cardiopulmonary resuscitation equipment should be readily available. The risks and benefits of re-administering Pombiliti following anaphylaxis or severe allergic reaction should be carefully considered, and appropriate resuscitation measures made available. Risk of acute cardiorespiratory failure in susceptible patients: Patients with acute underlying respiratory illness or compromised cardiac and/or respiratory function may be at risk of serious exacerbation of their cardiac or respiratory compromise during infusions. Appropriate medical support and monitoring measures should be readily available during Pombiliti infusion. Immune complex-related reactions: Immune complex-related reactions have been reported with other ERTs in patients who had high IgG antibody titres, including severe cutaneous reactions and nephrotic syndrome. If immune complex-related reactions occur, discontinuation of the administration of Pombiliti should be considered and appropriate medical treatment should be initiated. The risks and benefits of re-administering Pombiliti following an immune complex-related reaction should be reconsidered for each individual patient. Contraception in females: Reliable contraceptive measures must be used by women of childbearing potential during treatment with Pombiliti in combination with miglustat, and for 4 weeks after discontinuing treatment. Pregnancy: Pombiliti in combination with miglustat therapy is not recommended during pregnancy. Breast feeding: It is not known if Pombiliti and miglustat are secreted in human breast milk. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Pombiliti in combination with miglustat therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. Summary of the safety profile: The most commonly reported adverse reactions only attributable to Pombiliti were chills (4.0%), dizziness (2.6%), flushing (2.0%), somnolence (2.0%), chest discomfort (1.3%), cough, (1.3%), infusion site swelling (1.3%), and pain (1.3%). Reported serious adverse reactions only attributable to Pombiliti were urticaria (2.0%), anaphylaxis (1.3%), pyrexia (0.7%), presyncope (0.7%), dyspnoea (0.7%), pharyngeal oedema (0.7%), wheezing (0.7%), and hypotension (0.7%). Refer to SmPC for full list.
4
Opfolda (miglustat) 65 mg hard capsules Important Safety Information
Posology and Method of Administration: Opfolda must be used in combination with Pombiliti. The recommended dose is to be taken orally every other week and is based on body weight. Opfolda should be taken approximately 1 hour but no more than 3 hours before the start of the Pombiliti infusion. Paediatric population: The safety and efficacy of Opfolda in combination with Pombiliti therapy in paediatric patients less than 18 years old have not yet been established. No data are available. Contraindications: Hypersensitivity to the active substance or to any of the excipients. Contraindication to cipaglucosidase alfa. Food Interaction: Patients should fast for 2 hours before and 2 hours after taking Opfolda. Contraception in females: Reliable contraceptive measures must be used by women of childbearing potential during treatment with Opfolda in combination with Pombiliti, and for 4 weeks after discontinuing treatment. Pregnancy: Opfolda crosses the placenta. Opfolda in combination with Pombiliti therapy is not recommended during pregnancy. Breast feeding: It is not known if Opfolda and Pombiliti are secreted in human breast milk. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Opfolda in combination with Pombiliti therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman. Summary of the safety profile: The most commonly reported adverse reaction only attributable to Opfolda 65 mg was constipation (1.3%). Refer to SmPC for full list.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on Twitter and LinkedIn.
Non-GAAP Financial Measures
In addition to financial information prepared in accordance with U.S. GAAP, this press release also contains adjusted financial measures that we believe provide investors and management with supplemental information relating to operating performance and trends that facilitate comparisons between periods and with respect to projected information. These adjusted financial measures are non-GAAP measures and should be considered in addition to, but not as a substitute for, the information prepared in accordance with U.S. GAAP. We typically exclude certain GAAP items that management does not believe affect our basic operations and that do not meet the GAAP definition of unusual or non-recurring items. Other companies may define these measures in different ways. When we provide our expectation for non-GAAP operating expenses on a forward-looking basis, a reconciliation of the differences between the non-GAAP expectation and the corresponding GAAP measure generally is not available without unreasonable effort due to potentially high variability, complexity and low visibility as to the items that would be excluded from the GAAP measure in the relevant future period, such as unusual gains or losses. The variability of the excluded items may have a significant, and potentially unpredictable, impact on our future GAAP results.
5
Forward Looking Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, manufacturing and supply plans, financing plans, and the projected revenues and cash position for the Company. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing, and outcomes of discussions with regulatory authorities, including as they are impacted by COVID-19 related disruption, are based on current information. The potential impact on operations from the COVID-19 pandemic is inherently unknown and cannot be predicted with confidence and may cause actual results and performance to differ materially from the statements in this release, including without limitation, because of the impact on general political and economic conditions, including as a result of efforts by governmental authorities to mitigate COVID-19, such as travel bans, shelter in place orders and third-party business closures and resource allocations, manufacturing and supply chain disruptions and limitations on patient access to commercial or clinical product. In addition to the impact of the COVID-19 pandemic, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in our business, including, without limitation: the potential that results of clinical or preclinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities, including the FDA, EMA, MHRA, and PMDA, may not grant or may delay approval for our product candidates; the potential that required regulatory inspections may be delayed or not be successful and delay or prevent product approval; the potential that we may not be successful in commercializing Galafold and/or Pombiliti and Opfolda in Europe, the UK, the US and other geographies; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we may not be able to manufacture or supply sufficient clinical or commercial products; and the potential that we will need additional funding to complete all of our studies, the manufacturing, and commercialization of our products. With respect to statements regarding corporate financial guidance and financial goals and the expected attainment of such goals and projections of the Company's revenue and cash position, actual results may differ based on market factors and the Company's ability to execute its operational and budget plans. In addition, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2022, and on Form 10-Q for the quarter ended September 30, 2023, to be filed today. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update this news release to reflect events or circumstances after the date hereof.
CONTACT:
Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809
Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Communications
dmoore@amicusrx.com
(609) 662-5079
FOLD-G
6
TABLE 1
Amicus Therapeutics, Inc.
Consolidated Statements of Operations
(Unaudited)
(in thousands, except share and per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Net product sales | $ | 103,501 | $ | 81,691 | $ | 284,274 | $ | 241,137 | ||||||||
| Cost of goods sold | 9,946 | 13,436 | 26,002 | 29,215 | ||||||||||||
| Gross profit | 93,555 | 68,255 | 258,272 | 211,922 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 40,704 | 52,970 | 117,352 | 212,806 | ||||||||||||
| Selling, general, and administrative | 65,651 | 47,272 | 205,031 | 158,767 | ||||||||||||
| Changes in fair value of contingent consideration payable | 1,995 | 567 | 2,583 | (506 | ) | |||||||||||
| Loss on impairment of assets | — | — | 1,134 | 6,616 | ||||||||||||
| Depreciation and amortization | 2,228 | 1,286 | 5,691 | 4,031 | ||||||||||||
| Total operating expenses | 110,578 | 102,095 | 331,791 | 381,714 | ||||||||||||
| Loss from operations | (17,023 | ) | (33,840 | ) | (73,519 | ) | (169,792 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest income | 1,471 | 563 | 5,407 | 1,052 | ||||||||||||
| Interest expense | (12,986 | ) | (9,620 | ) | (37,322 | ) | (26,024 | ) | ||||||||
| Other income (expense) | 3,833 | 13,634 | (13,007 | ) | 22,804 | |||||||||||
| Loss before income tax | (24,705 | ) | (29,263 | ) | (118,441 | ) | (171,960 | ) | ||||||||
| Income tax benefit (expense) | 3,128 | (4,023 | ) | 700 | (8,743 | ) | ||||||||||
| Net loss attributable to common stockholders | $ | (21,577 | ) | $ | (33,286 | ) | $ | (117,741 | ) | $ | (180,703 | ) | ||||
| Net loss attributable to common stockholders per common share — basic and diluted | $ | (0.07 | ) | $ | (0.12 | ) | $ | (0.40 | ) | $ | (0.63 | ) | ||||
| Weighted-average common shares outstanding — basic and diluted | 295,759,435 | 289,223,709 | 293,314,167 | 288,841,092 | ||||||||||||
7
TABLE 2
Amicus Therapeutics, Inc.
Consolidated Balance Sheets
(Unaudited)
(in thousands, except share and per share amounts)
| September 30, 2023 | December 31, 2022 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 263,320 | $ | 148,813 | ||||
| Investments in marketable securities | 16,980 | 144,782 | ||||||
| Accounts receivable | 73,331 | 66,196 | ||||||
| Inventories | 56,936 | 23,816 | ||||||
| Prepaid expenses and other current assets | 52,689 | 40,209 | ||||||
| Total current assets | 463,256 | 423,816 | ||||||
| Operating lease right-of-use assets, net | 29,511 | 29,534 | ||||||
| Property and equipment, less accumulated depreciation of $25,018 and $22,281 at September 30, 2023 and December 31, 2022, respectively | 31,072 | 30,778 | ||||||
| Intangible assets, less accumulated amortization of $1,682 and $0 at September 30, 2023 and December 31, 2022, respectively | 21,318 | 23,000 | ||||||
| Goodwill | 197,797 | 197,797 | ||||||
| Other non-current assets | 21,130 | 19,242 | ||||||
| Total Assets | $ | 764,084 | $ | 724,167 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 23,154 | $ | 15,413 | ||||
| Accrued expenses and other current liabilities | 138,535 | 93,636 | ||||||
| Contingent consideration payable | — | 21,417 | ||||||
| Operating lease liabilities | 7,765 | 8,552 | ||||||
| Total current liabilities | 169,454 | 139,018 | ||||||
| Long-term debt | 394,071 | 391,990 | ||||||
| Operating lease liabilities | 52,454 | 51,578 | ||||||
| Deferred reimbursements | 5,906 | 4,656 | ||||||
| Deferred income taxes | — | 4,939 | ||||||
| Other non-current liabilities | 8,962 | 8,939 | ||||||
| Total liabilities | 630,847 | 601,120 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Common stock, $0.01 par value, 500,000,000 shares authorized, 290,667,041 and 281,108,273 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively | 2,890 | 2,815 | ||||||
| Additional paid-in capital | 2,787,275 | 2,664,744 | ||||||
| Accumulated other comprehensive loss: | ||||||||
| Foreign currency translation adjustment | (6,573 | ) | (11,989 | ) | ||||
| Unrealized loss on available-for-sale securities | (195 | ) | (116 | ) | ||||
| Warrants | 71 | 83 | ||||||
| Accumulated deficit | (2,650,231 | ) | (2,532,490 | ) | ||||
| Total stockholders’ equity | 133,237 | 123,047 | ||||||
| Total Liabilities and Stockholders’ Equity | $ | 764,084 | $ | 724,167 | ||||
8
TABLE 3
Amicus Therapeutics, Inc.
Reconciliation of Non-GAAP Financial Measures
(in thousands)
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Total operating expenses - as reported GAAP | $ | 110,578 | $ | 102,095 | $ | 331,791 | $ | 381,714 | ||||||||
| Research and development: | ||||||||||||||||
| Stock-based compensation | 4,380 | 5,428 | 16,987 | 19,172 | ||||||||||||
| Selling, general and administrative: | ||||||||||||||||
| Stock-based compensation | 12,131 | 9,344 | 50,995 | 38,714 | ||||||||||||
| Loss on impairment of assets | — | — | 1,134 | 6,616 | ||||||||||||
| Changes in fair value of contingent consideration payable | 1,995 | 567 | 2,583 | (506 | ) | |||||||||||
| Depreciation and amortization | 2,228 | 1,286 | 5,691 | 4,031 | ||||||||||||
| Total operating expense adjustments to reported GAAP | 20,734 | 16,625 | 77,390 | 68,027 | ||||||||||||
| Total operating expenses - as adjusted | $ | 89,844 | $ | 85,470 | $ | 254,401 | $ | 313,687 | ||||||||
9
